Identification of adverse events after vaccination increases awareness of vaccine-associated complications, leading to early diagnosis and treatment.
Evidence remains scarce on the association between the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) and sudden sensorineural hearing loss (SSNHL).
We assess the association between the BNT162b2 mRNA COVID-19 vaccine and SSNHL.
This retrospective, population-based cohort study was performed from December 20, 2020, to May 31, 2021, using data from the largest health care organization in Israel.
Patients 16 years or older who received the first vaccine dose between December 20, 2020, and April 30, 2021, and the second vaccine dose between January 10, 2021, and April 30, 2021, were included.